Join the launch webinar: Advancing Aging in Place of Choice
New Resource: DECODE CRS: Accelerating safer, scalable immunotherapy
New from the AMA: The physicians role in the AI era
NEW RESOURCE: Digital measures set for common mental health disorders
Digital measures offer the clinical trials community unparalleled insights into people’s real-life experiences, enhancing our understanding of numerous conditions. So, why haven’t we implemented digital endpoints on a larger scale?
Findings from research conducted by DiMe, Tufts Center for the Study of Drug Development, Johnson & Johnson, Roche, Genentech, UCB, Bayer, Takeda, and MindMed, now published in the Journal of Clinical & Translational Science, showcase evidence of significant cost reductions and financial benefits tied to leveraging digital endpoints in trials.
Watch the recording
View the slides